Gal-3 has pathogenic activity at the level of cancer, inflammatory and fibroproliferative diseases, such as pulmonary, cardiac, and hepatic fibrosis, and therefore, depending on the disease, Gal-3 is increased in different types of cells, which include macrophages, fibroblasts, and carcinogenic cells (251). Here, LGALS3 is linked to glycogen storage disease VI.